(Reuters) – Bluebird bio Inc on Friday set a worth for its gene remedy, Zynteglo, at 1.58 million euros ($1.78 million) over 5 years, after successful conditional approval in Europe this month to deal with a uncommon genetic blood dysfunction.

FILE PHOTO: Brad Zakes (L), founding father of Ethan Zakes Basis/CEO of Cerevast Medical, and Nick Leschly, CEO of bluebird bio on the opening of Swiss pharmaceutical group Lonza’s devoted cell and gene remedy facility in Houston, Texas, U.S., April 10, 2018. REUTERS/Daniel Kramer/File Picture

The corporate proposed an installment plan, with 315,000 euros paid up entrance and 4 extra annual funds due solely…



Source link

Please follow and like us: